BUB1 and neoplasm: BUB1 inhibition reduced tumor xenograft growth [14,18] and sensitized cancer cells to taxanes, ATR, or PARP inhibitors, confirming BUB1 as a therapeutic target for enhancing the efficacy of chemotherapies and targeted therapies [19].